Intratracheal Budesonide for Extremely Preterm Infants

Preterm birth is the greatest cause of neonatal mortality and morbidity, with infants born extremely preterm at highest risk. Author Brett J. Manley, PhD, the Royal Women’s Hospital, Melbourne, Australia, discusses a new study of the effect of intratracheal corticosteroid administration on survival free of bronchopulmonary dysplasia in preterm infants, with JAMA Deputy Editor Tracy A. Lieu, MD, MPH. Related Content: Intratracheal Budesonide Mixed With Surfactant for Extremely Preterm Infants